Sofie Denies

Immunogenicity Risk Profile of Nanobodies

Chloé Ackaert, Natalia Smiejkowska, Catarina Xavier et al. · Frontiers in Immunology · 2021 · 218 citations · Full text

Pharmacy, Immunology, Oncology +17

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Bruno Gomes, Grégory Driessens, Derek W. Bartlett et al. · Molecular Cancer Therapeutics · 2018 · 85 citations · Full text

Medicine, Immunology, Oncology +17

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

Julie Preillon, Julia Cuende, Virginie Rabolli et al. · Molecular Cancer Therapeutics · 2020 · 65 citations · Full text

Life Sciences, Immunology, Oncology +17

Comparison of the Adipose and Luminal Mammary Gland Compartment as Orthotopic Inoculation Sites in a 4T1-Based Immunocompetent Preclinical Model for Triple-Negative Breast Cancer

Jonas Steenbrugge, Koen Breyne, Sofie Denies et al. · Journal of Mammary Gland Biology and Neoplasia · 2016 · 50 citations

Medicine, Immunology, Oncology +11

Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer

Laetitia Cicchelero, Sofie Denies, Hendrik Haers et al. · Veterinary and Comparative Oncology · 2016 · 35 citations

Life Sciences, Immunology, Oncology +17